Slide 1: Genetic based preventative health platform
For personal use only Genetic based preventative health platform Personalised, Precision medicine. ASX:GTG NASDAQ: GENE Investor Presentation October 2020 Approved by the Board of Directors Genetic Technologies Limited 60-66 Hanover Street Fitzroy, 3065 Australia Coming soon T: +61 3 8412 7000
Slide 2: Notice: Forward looking statements
Notice: Forward looking statements For personal use only The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may re
Slide 3: Genetic Technologies - Leader in Genomics
Genetic Technologies - Leader in Genomics For personal use only F Over a decade developing polygenic risk scores - for major oncological, metabolic and degenerative diseases F Strong scientific leadership under Dr Richard Allman – a pioneer in the development of polygenic risk scores F Delivering be
Slide 4: Background to Genomics - The Human Genome Project
Background to Genomics - The Human Genome Project For personal use only F In 2003 scientists mapped the human genome – the three-billion-plus base pairs of DNA that create a living person F Significant advances in genomics are influencing the way physicians practice medicine in the 21st century RISK
Slide 5: Our Platform - Polygenic Risk Score (PRS)
Our Platform - Polygenic Risk Score (PRS) For personal use only F Most common complex diseases are a result of many genes acting in concert F Our tests predicts a patient’s risk of developing a specific disease by analysing DNA variants across a genome F Large genome-wide association study (GWAS) da
Slide 6: PRS and Risk Stratification
PRS and Risk Stratification For personal use only BREAST CANCER - COLORECTAL CANCER - WOMEN WITH FAMILY HISTORY PEOPLE WITH FAMILY HISTORY <20 20-40 40-60 60-80 80+ 2 FIRST DEGREE RELATIVES WITH CRC HIGH HIGHEST QUINTILE SNP RISK RISK CUMULATIVE RISK OF CRC 0.30 30% AVERAGE SNP RISK 0.25 25% LOWEST
Slide 7: Differences between PRS & Genetic Testing
Differences between PRS & Genetic Testing For personal use only F Current genetic testing only captures hereditary forms of the disease (e.g. inherited cancer risk representing 5-15% of all Breast Cancer (BC) F PRS captures sporadic (non-inherited) disease - the most common form of all diseases (rep
Slide 8: GeneType for Breast Cancer
7 For personal use only GeneType for Breast Cancer 8
Slide 9: GeneType for Breast Cancer
GeneType for Breast Cancer For personal use only F 1 in 8 women will develop breast cancer in BREAST CANCER their lifetime BRCA VARIANT* F It is the number 1 cancer in Australia with 3000 (INHERITED) NO BRCA deaths per year and 20,000 diagnosed this VARIANT* (FAMILIAL) year alone 5% F 85% of women w
Slide 10: Screening compliance & breast density risks
Screening compliance & breast density risks For personal use only UP-TO-DATE MAMMOGRAM BREAST DENSITY 37% 43% NON-COMPLIANT DENSE BREAST TISSUE 63% 57% COMPLIANT Over 1/3 of women are Nearly half of all women have a not screened significant risk factor - dense breast tissue Haber et al 2012 American
Slide 11: GeneType Age Coverage
GeneType Age Coverage For personal use only F Current Government screening starts at 50 years of age F Over 20% of women under the age of 50 are diagnosed with breast cancer DIAGNOSIS OF BREAST CANCER IN PERSONS BY AGE AT DIAGNOSIS, AUSTRALIA 2020 3000 2,816 2,782 2500 2,532 NUMBER OF CASES 2,215 20
Slide 12: GeneType test for Breast Cancer
GeneType test for Breast Cancer For personal use only F First-to-market F Clinically validated F Covers up to 85% of all breast cancers F Simple cheek swab F Clinically actionable results with a 5 year and lifetime risk assessment F Validated for use in Caucasion women over 35 GeneType accurately pr
Slide 13: Better Medical Outcomes
Better Medical Outcomes For personal use only F Better compliance with screening F Enhanced surveillance of high-risk women F Up to 48% of interval cancers would be detected by stratified screening based on risk F Lifestyle interventions: Cessation of smoking, lowering BMI, increase activity F 5-yea
Slide 14: Better Financial Outcomes
Better Financial Outcomes For personal use only STAGE 1 $55,000 ...................................................................... Early diagnosis means lower STAGE cost burden 2 $100,000 ...................................................................... & better outcomes STAGE STAGE 3 + 4 .
Slide 15: GeneType for Colorectal Cancer
For personal use only GeneType for Colorectal Cancer 15
Slide 16: Colorectal Cancer
Colorectal Cancer For personal use only F 1 in 11 men and 1 in 16 women will contract colorectal cancer in their lifetime F Second deadliest cancer-responsible for an average 100 deaths per week in Australia F Current screening begins at 50 with approximately 10% developing the cancer earlier F Over
Slide 17: GeneType for Colorectal Cancer
GeneType for Colorectal Cancer For personal use only F Covers 95% of colorectal cancer F Improved screening compliance with an easy to use test F Examines risk in individuals before they are eligible for routine screening F Simple cheek swab F Clinically actionable results with a 5-year, 10-year and
Slide 18: Better Medical Outcomes
Better Medical Outcomes For personal use only BOWEL CANCER STAGE OF DISTRIBUTION 5-YEAR SURVIVAL RATES NBCSP* UNSCREENED ESTIMATES SCREENED STAGE 1 43% 17% STAGE 1 87% STAGE 2 27% 37% STAGE 2 81% STAGE 3 27% 29% STAGE 3 64% STAGE 4 3% 18% STAGE 4 16% F Earlier screening leads to greater detection of
Slide 19: Better Channelling of Resources
Better Channelling of Resources For personal use only Screening More frequent & potentially earlier screening Colonoscopy for high-risk Resources targeted to those at a higher Preventive Medication risk of developing Low-dose aspirin (100-300 mg/day) colorectal cancer Lifestyle Weight management, al
Slide 20: Better Financial Outcomes
Better Financial Outcomes For personal use only F Bowel cancer treatment costs have soared by over $50K per advanced case BOWEL CANCER COST INCREASE CURRENT PREVIOUS ESTIMATES (1999 INCREASE ESTIMATES COSTS) STAGE 1 $30,890 $17,148 46% STAGE 2 $47,534 $33,364 17% STAGE 3 $74,225 $25,771 180% STAGE 4
Slide 21: Coming Soon
Coming Soon For personal use only Prostate Type 2 Diabetes Cardiovascular Disease COVID-19 SDR Melanoma genetype.com 21
Slide 22: COVID-19 SDR (Serious disease risk)
COVID-19 SDR (Serious disease risk) For personal use only World first genetic risk test that predicts your risk of hospitalisation & life threatening complications Genetype for COVID-19 SDR F World first F Combines genetic risk with clinical risk F Up to 111% better at identifying risk than clinical
Slide 23: Expansion/Growth Roadmap
Expansion/Growth Roadmap For personal use only GENETICS RISK Stratification Lifestyle Disease Microbiome testing Prediction and ancestry Disease Diagnosis/ Therapeutic recurrence screening Cell-Free DNA (cfDNA) Genetically inspired Circulating Tumor Cells (CTC) medical therapies 23
Slide 24: Product Development
Product Development For personal use only Between 2010 - 2019 F Developed PRS Test Kits for BC (Breast Cancer) & CRC (Colorectal Cancer) F 2 to 5 years per test to develop F Average cost per test in excess of $2M AUD 2020 onwards F Collaborate with world class medical groups such as MSK, University
Slide 25: Expansion/Growth/Market Size
Expansion/Growth/Market Size For personal use only Lifestyle ONCOLOGY GENETIC BC, CRC, PC, Ancestry Melanoma TECHNOLOGIES /Microbiome (Genetype) CVD Pharmoco- (Heart Disease) genetics IHD, AF Metabolic Diseases COVID-19 SDR Diabetes Mental Health 25
Slide 26: Sales & Distribution by Region and Method
For personal use only SALES & DISTRIBUTION SALES & DISTRIBUTION by Region by Method • Certified by US regulators CLIA to sell into • CIT (Consumer initiated testing and online sales the USA and marketing platform with medical supervision) due for launching in Australia & the • Certified by Australia
Slide 27: Corporate
Corporate For personal use only • Dual listed on ASX and the Nasdaq the worlds largest biotech exchange Listings In 2001 and 2005 respectively • 600 shares on the ASX equate to 1 ADR (American Depository Receipts) in the USA which are interchangeable via custodian bank of Mellon with 70% of stock he
Slide 28: Our Board
Our Board For personal use only Dr. Jerzy “George” Muchnicki Dr. Lindsay Wakefield MBBS MBBS Executive Director & Chief Executive Non-Executive Director Officer (Interim Mr. Peter Rubinstein Mr Nick Burrows BSc, BEc, LLB BSc, BEc, LLB Chairman & Non-Executive Director B.Com, FAICD, FCA, FGIA, FTIA,